A Single Arm, Phase II Study of Neoadjuvant Chemoradiotherapy With Capecitabine Plus Simvastatin in Locally Advanced Rectal Cancer Patients
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 May 2019
Price : $35 *
At a glance
- Drugs Capecitabine (Primary) ; Simvastatin (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- 17 May 2019 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.
- 17 May 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 17 May 2019 Status changed from recruiting to active, no longer recruiting.